Investor Newsletter

Issue 07 2022

MicroPort®

MicroPort NeuroTech™ Debuts on Main Board of HKEX

On 15 July, MicroPort Neurotech Limted (02172.HK, "MicroPort NeuroTech™" of the "Company"), a pioneering company in the field of neurovascular interventional treatment, announced it has successfully listed on the Main Board of the Hong Kong Stock Exchange(HKEX).

Mr. Zhiyong Xie, President of MicroPort NeuroTech™ stated, "In the last decade, MicroPort NeuroTech™ recorded rapid development with a number of innovative products achieving technical breakthroughs and extensive commercialization. After listing, MicroPort NeuroTech™ will further accelerate the process of R&D and industrialization, to provide comprehensive medical solutions that can prolong the lives of patients with cerebrovascular diseases worldwide."

Mr. Bo Peng, the Chief Marketing Officer of MicroPort® Group and Chairman of MicroPort NeuroTech™ commented, "The listing of MicroPort NeuroTech™ on the HKEX is an important milestone in its development. In the future, MicroPort NeuroTech™ will further strengthen corporate governance, fulfill our mission and social responsibilities. We are committed to meeting the cutting-edge development needs of cerebrovascular diseases, serving patients and rewarding investors with better performance."

MicroPort® Participates in CIT 2022 and Hosts Joint Satellite Session

MicroPort Scientific Corporation ("MicroPort®"), together with its subsidiaries Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort® Coronary") and MicroPort CardioFlow Medtech Corporation ("CardioFlow Medtech"), recently participated in the 20th Chinese Interventional Therapeutic Congress (CIT 2022), an online conference hosted by the Chinese Medical Association bringing together leading experts in the field of interventional cardiology. MicroPort® organized a joint satellite session to showcase multiple lines of business.

"Through robust clinical trials, the Firehawk® stent, the Firesorb® stent, and the VitaFlow® valve are all proving to the world how the extraordinary technology of MicroPort® products will empower patients and physicians with more choices and information" commented Prof. Bo Xu in the satellite session, "when developing products, MicroPort® focuses on scientific evaluation and relies on clinical medicine methodologies and randomized studies. We look forward to MicroPort®'s smart products going global and benefiting more patients."

CIT Online 20th ANNIVERSARY 2022
COOPERATION · INNOVATION · TRANSITION
第二十届中国介入心脏病学大会

MicroPort

Firehawk Pro™ Coronary Rapamycin Target Eluting Stent System Receives NMPA Approval for Marketing

Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") has recently received approval from the Chinese National Medical Products Administration (NMPA) to market its Firehawk Pro™ Coronary Rapamycin Target Eluting Stent System ("Firehawk Pro™ Stent").

The approval of Firehawk Pro™ Stent further enriches the product line for cardiovascular interventional treatment. In the future, MicroPort® will continue to invest in product innovation and technology development to bring more high-quality and affordable integrated solutions for patients.

MicroPort

MicroPort® CRM Receives CE Mark Approval for INVICTA™ Defibrillation Leads

MicroPort® CRM, a pioneering company in the field of Cardiac Rhythm management, headquartered in France, has recently received CE Mark approval under the new Medical Device Regulation (MDR – 2017/745) for its INVICTA™ family of defibrillation leads.

"Bringing INVICTA™ to the market is a critical and major milestone for MicroPort® CRM," said Benoît Clinchamps, President of MicroPort® CRM. "With the INVICTA™ approval, we have succeeded in completely renewing our portfolio of ICD and CRT-D devices as well as their associated leads, and now can offer to the industry our most advanced lineup of ICD therapeutic solutions and technologies. We have now unleashed the full potential of our ICD portfolio and look forward to it becoming a significant revenue growth driver and profitability driver for our company."

MicroPort



MSC Announces the First Clinical Use of The First Rega™ MRI-Conditional Implantable Pacemaker in China

MicroPort® Soaring CRM (Shanghai) Co., Ltd. ("MSC") recently announced the first batch of the Rega™ MRI-conditional implantable pacemakers was used at several medical centers, including Fuwai Hospital Chinese Academy of Medical Sciences, Zhongshan Hospital; affiliated to Fudan University, Shanxi Institute of Cardiovascular Diseases, First Affiliated Hospital of Xinjiang Medical University, First Affiliated Hospital of Dalian Medical University, and First Affiliated Hospital of Zhengzhou University. These implants mark the first official clinical use of a MRI-conditional pacemaker in China.

Dr. Qiyi Luo, Chairman of MSC, said, "MSC has always been committed to providing a comprehensive solution for patients with cardiac arrhythmias. We will continue to serve the patients and launch a full range of innovative technologies and quality products for heart rhythm management by keeping clinical needs in mind. We will also actively cooperate with doctors to advance the promotion and application of pacing therapy in China."

Endovastec™ Reewarm™ PTX DCB PTA Catheter Receives Marketing Approval in Brazil

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™") announced that it has received registration approval from the Brazilian Health Regulatory Agency (ANVISA) for its independently developed Reewarm™ paclitaxel (PTX) drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) Catheter ("Reewarm™ PTX").

Mr Qing Zhu, President of Endovastec™, stated: "The Reewarm™ PTX has shown excellent clinical performance since its launch. It has provided a better surgical solution for the treatment of peripheral artery diseases, and elevated our market competitiveness in the field of peripheral vascular intervention. In the future, Endovastec™ will continue to develop and produce more high-quality, high-end medical devices to benefit more patients worldwide."

Endovastec™ Presents Flagship Products at CICE 2022

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™") held a seminar recently at the International Congress of Endovascular Surgery (Congresso International de Cirurgia Endovascular, CICE 2022) in Brazil, engaging local and global experts.

As the world's first market-approved branched aortic stent-graft, the innovative Castor™ Branched Aortic Stent-Graft System developed by Endovastec™ was presented at the CICE conference after its debut in Brazil in 2020, attracting attention and recognition by the vascular surgery community in South America for its underlying technology. In the future, Endovastec™ will continue to be committed to introducing more and better innovative products for aortic and peripheral vascular interventions for the benefit of more patients with blood circulation diseases worldwide.

MicroPort

Investor Newsletter

Issue 07 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com